Supernus Pharmaceuticals pharma deals closing an announced private offering of $90 million financing.
The net proceeds from this pharma deals financing offering were approximately $86.4 million, after deducting discounts to the initial purchasers and estimated offering expenses payable by Supernus.
Contemporaneously with the closing of the offering, Supernus used approximately $19.6 million of the net proceeds to repay in full its borrowings under and terminate its secured credit facility.
Supernus intends to use the remainder of the pharma deals net proceeds to fund the commercialization of its approved and tentatively approved epilepsy drugs, Oxtellar XR and Trokendi XR, to continue development of its pipeline products and for other general corporate purposes.
Daily news stories
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity